Reata Pharmaceuticals, a Texas-based clinical-stage biopharmaceutical company, is making strides in identifying, developing, and commercializing novel therapeutics for patients with serious or life-threatening diseases. The company is at the forefront of Phase 3 clinical trial programs, including bardoxolone methyl for the treatment of chronic kidney disease caused by Alport syndrome and a form of pulmonary arterial hypertension associated with connective tissue disease. In addition, Reata Pharmaceuticals is developing omaveloxolone to treat Friedreich's ataxia and various forms of CKD, such as type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and more. Reata Pharmaceuticals is also working on RTA 901 for neurological diseases and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In a strategic collaboration agreement, the biopharmaceutical company is partnering with Kyowa Kirin to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Asia. They have also teamed up with AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications, excluding renal, cardiovascular, and metabolic indications. Founded in 2002, Reata Pharmaceuticals continues to make strides in the biopharmaceutical industry by putting their innovative ideas into action for the betterment of patient care.